Preparing for the uncertain yet inevitable: Off‐label combinations of antiviral agents in hepatitis C virus
Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub, Kenneth K. Tanabe – 21 October 2013 – Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer‐related mortality in the United States.
Interleukin‐22, liver progenitor cells, and liver cancer
Dechun Feng – 21 October 2013
Preparing for the uncertain yet inevitable: Off‐label combinations of antiviral agents in hepatitis C virus
Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013
Higher viral load, higher hepatitis B surface antigen clearance?
Gin‐Ho Lo – 21 October 2013
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers
Andrea Lisotti, Francesco Azzaroli, Marco Montagnani, Giuseppe Mazzella – 21 October 2013
The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis
Darragh Duffy, Rasha Mamdouh, Melissa Laird, Charlotte Soneson, Lenaig Le Fouler, Maï El‐Daly, Armanda Casrouge, Jérémie Decalf, Amal Abbas, Noha Sharaf Eldin, Magnus Fontes, Mohamed Abdel‐Hamid, Mostafa K. Mohamed, Mona Rafik, Arnaud Fontanet, Matthew L. Albert – 21 October 2013 – Viral hepatitis is the leading cause of liver disease worldwide and can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus.
Reply
Stuart C Gordon, Eduardo Bruno Martins, Leland J. Yee – 21 October 2013
Oral mucosal health in liver transplant recipients and controls
Jaana Helenius‐Hietala, Hellevi Ruokonen, Lisa Grönroos, Harri Rissanen, Miira M. Vehkalahti, Liisa Suominen, Helena Isoniemi, Jukka H. Meurman – 18 October 2013 – Immunosuppressive drugs and other medications may predispose patients to oral diseases. Data on oral mucosal health in recipients of liver transplantation (LT) are limited. We, therefore, recruited 84 LT recipients (64 with chronic liver disease and 20 with acute liver failure) for clinical oral examinations in a cross‐sectional, case‐control study. Their oral health had been clinically examined before transplantation.
Transjugular intrahepatic portosystemic shunts in liver transplant recipients
Alexander R. Bonnel, Chalermrat Bunchorntavakul, K. Rajender Reddy – 18 October 2013 – The insertion of a transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive procedure used to relieve the signs and symptoms of portal hypertension in patients with liver disease. The most common indications for placement are refractory ascites and variceal hemorrhage. In properly selected candidates, TIPS placement can serve as a bridge to liver transplantation.